- Home
- RARE
RARE
Ultragenyx Pharmaceutical Inc.
as 05-15-2025 4:00pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | N/A | IPO Year: | 2014 |
| Target Price: | $94.00 | AVG Volume (30 days): | 985.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.59 - $60.37 | Next Earning Date: | 05-06-2025 |
| Revenue: | $590,689,000 | Revenue Growth: | 33.46% |
| Revenue Growth (this year): | 19.3% | Revenue Growth (next year): | 29.21% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Crombez Eric | RARE | EVP and Chief Medical Officer | Apr 21 '25 | Sell | $37.18 | 762 | $28,901.42 | 71,680 | |
| Horn Howard | RARE | Chief Financial Officer | Mar 6 '25 | Sell | $40.40 | 1,785 | $72,114.00 | 106,169 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Mar 1 '25 | Sell | $42.10 | 967 | $40,710.70 | 50,265 | |
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 1 '25 | Sell | $42.10 | 6,028 | $253,778.80 | 265,238 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Mar 1 '25 | Sell | $42.10 | 12,846 | $540,816.60 | 75,287 | |
| Pinion John Richard | RARE | See Remarks | Mar 1 '25 | Sell | $42.10 | 14,439 | $607,881.90 | 107,766 | |
| Crombez Eric | RARE | EVP and Chief Medical Officer | Mar 1 '25 | Sell | $42.10 | 8,945 | $376,584.50 | 71,680 | |
| Harris Erik | RARE | EVP & Chief Commercial Officer | Mar 1 '25 | Sell | $42.10 | 15,103 | $635,836.30 | 87,855 | |
| KAKKIS EMIL D | RARE | President & CEO | Feb 28 '25 | Sell | $42.29 | 98,434 | $4,153,571.40 | 641,731 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Feb 27 '25 | Sell | $42.84 | 2,990 | $128,223.90 | 75,287 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
Simply Wall St.
6 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
TipRanks
7 days ago
Ultragenyx price target lowered to $100 from $140 at Truist
Simply Wall St.
7 days ago
Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
8 days ago
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
Thomson Reuters StreetEvents
8 days ago
Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call
Zacks
8 days ago
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
GuruFocus.com
9 days ago
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.